Andrea Erriquez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Erriquez has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Gianluca Campo
Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy
8 shared publications - Simone Biscaglia
Department of Cardiology, University of Ferrara, Ferrara, Italy
6 shared publications - Filippo Maria Verardi
Cardiology Unit Azienda Ospedaliero‐Universitaria di Ferrara Ferrara Italy
3 shared publications - Matteo Tebaldi
Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara, Cona, Italy
3 shared publications - Alberto Sarti
Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, 44124 Ferrara, Italy
2 shared publications Carlo Penzo
Cardiology Unit Azienda Ospedaliero‐Universitaria di Ferrara Ferrara Italy
2 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (4) , 1698-1706
Evaluating the Impact of Enhanced Stent Visualization on PCI Outcomes in Older Patients With Multivessel Disease
Background: Optimal stent expansion is a key determinant of long‐term outcomes after PCI. Intravascular imaging provides the most accurate assessment of stent deployment but remains underused, especially in older patients with MI and multivessel disease. ESV is an angiographic enhancement technology that may help detect gross stent underexpansion when advanced imaging is not feasible. Aims: To evaluate the procedural and clinical impact of enhanced stent visualization (ESV)‐guided percutaneous coronary intervention (PCI) in older patients with myocardial infarction (MI) and multivessel disease. Methods: In this prespecified sub‐study of the FIRE trial, we evaluated the impact of ESV use during PCI in older MI patients. Among 1445 enrolled patients, 331 underwent ESV‐guided PCI and 1114 standard angiography‐guided PCI. Procedural optimization triggered by ESV was defined as additional postdilation, extra stent implantation, or use of intravascular imaging. Minimal lumen diameter (MLD) was assessed before and after ESV‐guided optimization. Clinical outcomes were compared using multivariable and competing‐risk adjusted Cox models. Results: Operator‐driven optimization occurred in 85% of ESV cases, primarily through postdilation (96%). ESV guidance resulted in a significant MLD increase from 2.51 [2.22–2.87] to 2.93 [2.41–3.32] mm ( p < 0.001), yielding an acute luminal gain of 0.42 mm (95% CI 0.37–0.47). At 3 years, the composite primary endpoint (death, MI, stroke, or ischemia‐driven revascularization) was lower in the ESV group (adjusted HR 0.70, 95% CI 0.54–0.91; p = 0.008). Conclusions: In older MI patients with complex multivessel disease, ESV‐guided PCI was associated with greater procedural optimization, improved acute stent expansion, and lower long‐term adverse events. While not a substitute for intracoronary imaging, ESV represents a pragmatic and valuable adjunct to enhance PCI quality in settings where intravascular imaging is seldom performed. Trial Registration: ClinicalTrials.gov identifier NCT03772743.
- 21 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (4) , 1698-1706
Open AccessEvaluating the Impact of Enhanced Stent Visualization on PCI Outcomes in Older Patients With Multivessel Disease
Background: Optimal stent expansion is a key determinant of long‐term outcomes after PCI. Intravascular imaging provides the most accurate assessment of stent deployment but remains underused, especially in older patients with MI and multivessel disease. ESV is an angiographic enhancement technology that may help detect gross stent underexpansion when advanced imaging is not feasible. Aims: To evaluate the procedural and clinical impact of enhanced stent visualization (ESV)‐guided percutaneous coronary intervention (PCI) in older patients with myocardial infarction (MI) and multivessel disease. Methods: In this prespecified sub‐study of the FIRE trial, we evaluated the impact of ESV use during PCI in older MI patients. Among 1445 enrolled patients, 331 underwent ESV‐guided PCI and 1114 standard angiography‐guided PCI. Procedural optimization triggered by ESV was defined as additional postdilation, extra stent implantation, or use of intravascular imaging. Minimal lumen diameter (MLD) was assessed before and after ESV‐guided optimization. Clinical outcomes were compared using multivariable and competing‐risk adjusted Cox models. Results: Operator‐driven optimization occurred in 85% of ESV cases, primarily through postdilation (96%). ESV guidance resulted in a significant MLD increase from 2.51 [2.22–2.87] to 2.93 [2.41–3.32] mm ( p < 0.001), yielding an acute luminal gain of 0.42 mm (95% CI 0.37–0.47). At 3 years, the composite primary endpoint (death, MI, stroke, or ischemia‐driven revascularization) was lower in the ESV group (adjusted HR 0.70, 95% CI 0.54–0.91; p = 0.008). Conclusions: In older MI patients with complex multivessel disease, ESV‐guided PCI was associated with greater procedural optimization, improved acute stent expansion, and lower long‐term adverse events. While not a substitute for intracoronary imaging, ESV represents a pragmatic and valuable adjunct to enhance PCI quality in settings where intravascular imaging is seldom performed. Trial Registration: ClinicalTrials.gov identifier NCT03772743.
- Open Access
- 18 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6358
Residual Atherothrombotic Risk After Myocardial Infarction: Integrating Lipid, Inflammatory and Thrombotic Pathways
Despite major advances in reperfusion strategies and guideline-directed medical therapy, patients surviving myocardial infarction (MI) remain at substantial risk of recurrent cardiovascular events. Among the multiple determinants of post-MI cardiovascular risk, persistent atherothrombotic vulnerability remains a major therapeutic challenge despite guideline-directed secondary prevention. This review provides an integrated overview of residual atherothrombotic risk after MI, focusing on the complementary roles of lipid, inflammatory, and thrombotic pathways. Current evidence supports the use of biomarkers such as apolipoprotein B, lipoprotein(a), remnant cholesterol, triglyceride-rich lipoproteins, and high-sensitivity C-reactive protein to improve risk stratification beyond LDL-C. Landmark clinical trials have demonstrated that intensive lipid-lowering therapy, selected anti-inflammatory agents, and individualized antithrombotic strategies can further reduce recurrent cardiovascular events in appropriately selected patients. However, these pathogenic pathways rarely occur in isolation and frequently overlap, generating heterogeneous residual risk phenotypes. We propose a pragmatic multi-layered model in which lipid, inflammatory, and thrombotic mechanisms are viewed as interconnected biological processes rather than independent entities. This framework supports a personalized approach to secondary prevention based on comprehensive risk assessment, targeted therapeutic intensification, and longitudinal reassessment. Integrating these complementary domains may provide a framework for more individualized secondary prevention after MI, although its clinical utility requires prospective validation.
- 18 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6358
Open AccessResidual Atherothrombotic Risk After Myocardial Infarction: Integrating Lipid, Inflammatory and Thrombotic Pathways
Despite major advances in reperfusion strategies and guideline-directed medical therapy, patients surviving myocardial infarction (MI) remain at substantial risk of recurrent cardiovascular events. Among the multiple determinants of post-MI cardiovascular risk, persistent atherothrombotic vulnerability remains a major therapeutic challenge despite guideline-directed secondary prevention. This review provides an integrated overview of residual atherothrombotic risk after MI, focusing on the complementary roles of lipid, inflammatory, and thrombotic pathways. Current evidence supports the use of biomarkers such as apolipoprotein B, lipoprotein(a), remnant cholesterol, triglyceride-rich lipoproteins, and high-sensitivity C-reactive protein to improve risk stratification beyond LDL-C. Landmark clinical trials have demonstrated that intensive lipid-lowering therapy, selected anti-inflammatory agents, and individualized antithrombotic strategies can further reduce recurrent cardiovascular events in appropriately selected patients. However, these pathogenic pathways rarely occur in isolation and frequently overlap, generating heterogeneous residual risk phenotypes. We propose a pragmatic multi-layered model in which lipid, inflammatory, and thrombotic mechanisms are viewed as interconnected biological processes rather than independent entities. This framework supports a personalized approach to secondary prevention based on comprehensive risk assessment, targeted therapeutic intensification, and longitudinal reassessment. Integrating these complementary domains may provide a framework for more individualized secondary prevention after MI, although its clinical utility requires prospective validation.
- 23 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (7) , 3456-3464
Additional Value of Optical Coherence Tomography‐Derived Virtual Flow Reserve for Percutaneous Coronary Intervention Guidance
Background: The combination of imaging and physiology could provide the best guidance for complex and high‐risk interventional procedures (CHIP). Aims: The objective of the present study is to evaluate the difference in percutaneous coronary intervention (PCI) planning in CHIP patients between angiography, angiography‐derived fractional flow reserve (FFR), and the combination of imaging and physiology by means of optical coherence tomography plus virtual flow reserve (OCT‐VFR). Secondary objectives were to evaluate disease pattern, virtual stent length, and RVD according to the different plans. Methods: Among patients included in the AQVA‐I and II trials, we selected those receiving OCT ( n = 114). Physiology reconstruction based on OCT traces was obtained in 97 patients. One operator, blinded to the actual procedural plan and to post‐PCI result, planned the procedure according to angiography, angiography‐derived FFR, OCT, and OCT‐VFR. Results: OCT‐VFR plan was different compared to angiography and angiography‐derived FFR plans in 48% and 30% of the cases, respectively. OCT‐VFR plan was also different from OCT plans in 25% of the cases, mainly because of a different disease pattern leading to shorter treatment. Pattern of disease was more frequently focal in the angiography‐derived FFR plan if compared to OCT‐VFR plan ( p < 0.01). Stent length was different across different plans ( p for trend < 0.001) with angiography‐derived FFR with the shortest and OCT with the longest, respectively. Conclusions: OCT‐VFR provided a different PCI plan than both angiography and angiography‐derived FFR in more than one‐third of the cases. If compared to OCT alone, the OCT‐VFR plan was significantly shorter in terms of stent length. Trial Registration: ClinicalTrials.gov NCT05658952, NCT04664140.
- 23 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (7) , 3456-3464
Additional Value of Optical Coherence Tomography‐Derived Virtual Flow Reserve for Percutaneous Coronary Intervention Guidance
Background: The combination of imaging and physiology could provide the best guidance for complex and high‐risk interventional procedures (CHIP). Aims: The objective of the present study is to evaluate the difference in percutaneous coronary intervention (PCI) planning in CHIP patients between angiography, angiography‐derived fractional flow reserve (FFR), and the combination of imaging and physiology by means of optical coherence tomography plus virtual flow reserve (OCT‐VFR). Secondary objectives were to evaluate disease pattern, virtual stent length, and RVD according to the different plans. Methods: Among patients included in the AQVA‐I and II trials, we selected those receiving OCT ( n = 114). Physiology reconstruction based on OCT traces was obtained in 97 patients. One operator, blinded to the actual procedural plan and to post‐PCI result, planned the procedure according to angiography, angiography‐derived FFR, OCT, and OCT‐VFR. Results: OCT‐VFR plan was different compared to angiography and angiography‐derived FFR plans in 48% and 30% of the cases, respectively. OCT‐VFR plan was also different from OCT plans in 25% of the cases, mainly because of a different disease pattern leading to shorter treatment. Pattern of disease was more frequently focal in the angiography‐derived FFR plan if compared to OCT‐VFR plan ( p < 0.01). Stent length was different across different plans ( p for trend < 0.001) with angiography‐derived FFR with the shortest and OCT with the longest, respectively. Conclusions: OCT‐VFR provided a different PCI plan than both angiography and angiography‐derived FFR in more than one‐third of the cases. If compared to OCT alone, the OCT‐VFR plan was significantly shorter in terms of stent length. Trial Registration: ClinicalTrials.gov NCT05658952, NCT04664140.
- 8 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2469-2476
Functional Assessment of Intravascular Lithotripsy for Stent Underexpansion
Background: Stent underexpansion from severe calcification leads to adverse outcomes. While intravascular lithotripsy (IVL) is effective pre‐stenting, its role in treating stent underexpansion remains unclear. Methods: We conducted a multicenter, retrospective study of patients undergoing percutaneous coronary intervention (PCI) with IVL from January 2019 to 2025. Patients were categorized into two groups based on IVL use: the upfront group (IVL before stent placement) and the intrastent group (IVL for treating stent underexpansion). The outcomes included a quantitative flow ratio‐based trans‐stent gradient (QFR‐TSG) > 0 post‐PCI, target vessel failure, and major adverse cardiovascular events (MACE). Statistical analyses employed inverse probability of treatment weighting with logistic and Cox regression models and Kaplan−Meier survival curves. Results: A total of 166 consecutive patients were included, with 79 (47.6%) in the intrastent IVL group and 87 (52.4%) in the upfront IVL group. Compared to the upfront IVL group, patients treated with intrastent IVL had a higher prevalence of diabetes mellitus (49.4% vs. 19.5%, p < 0.001). QFR‐TSG > 0 was significantly more frequent in the intrastent IVL group (77.2% vs. 60.9%, p = 0.036). After IPTW adjustment, intrastent IVL was not significantly associated with increased MACE risk (OR 1.11; 95% CI 0.55–2.61; p = 0.240). Kaplan−Meier analysis similarly showed no difference in MACE‐free survival between groups over a mean follow‐up of 3.7 years (log‐rank p = 0.299). Conclusions: Intrastent IVL yields inferior functional results versus upfront IVL but appears safe and may serve as a useful rescue option for stent underexpansion.
- 8 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2469-2476
Functional Assessment of Intravascular Lithotripsy for Stent Underexpansion
Background: Stent underexpansion from severe calcification leads to adverse outcomes. While intravascular lithotripsy (IVL) is effective pre‐stenting, its role in treating stent underexpansion remains unclear. Methods: We conducted a multicenter, retrospective study of patients undergoing percutaneous coronary intervention (PCI) with IVL from January 2019 to 2025. Patients were categorized into two groups based on IVL use: the upfront group (IVL before stent placement) and the intrastent group (IVL for treating stent underexpansion). The outcomes included a quantitative flow ratio‐based trans‐stent gradient (QFR‐TSG) > 0 post‐PCI, target vessel failure, and major adverse cardiovascular events (MACE). Statistical analyses employed inverse probability of treatment weighting with logistic and Cox regression models and Kaplan−Meier survival curves. Results: A total of 166 consecutive patients were included, with 79 (47.6%) in the intrastent IVL group and 87 (52.4%) in the upfront IVL group. Compared to the upfront IVL group, patients treated with intrastent IVL had a higher prevalence of diabetes mellitus (49.4% vs. 19.5%, p < 0.001). QFR‐TSG > 0 was significantly more frequent in the intrastent IVL group (77.2% vs. 60.9%, p = 0.036). After IPTW adjustment, intrastent IVL was not significantly associated with increased MACE risk (OR 1.11; 95% CI 0.55–2.61; p = 0.240). Kaplan−Meier analysis similarly showed no difference in MACE‐free survival between groups over a mean follow‐up of 3.7 years (log‐rank p = 0.299). Conclusions: Intrastent IVL yields inferior functional results versus upfront IVL but appears safe and may serve as a useful rescue option for stent underexpansion.
- Open Access
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Patient-level outcomes of patients undergoing resorbable magnesium scaffold (RMS) implantation stratified according to different subgroups: a post-hoc analysis of SHERPA MAGIC study
Background: The SHERPA-MAGIC is an investigator-driven, multicenter, prospective, single-arm study that enrolled patients undergoing resorbable magnesium scaffold (RMS) implantation in 18 Italian centers. The results from the first 543 patients supported the safety and long-term performance of RMS in a real-world population. Purpose: The present post-hoc analysis aimed to assess differences in adverse events at patient-level (patient-oriented composite endpoints, POCE, defined as the composite of all-cause death, myocardial infarction -MI- and ischemia-driven coronary revascularization) at the longest follow-up between different subgroups of the final study population (n=543). Methods: We identified the subgroups according to different variables: age, sex, cardiovascular risk factors, clinical presentation, left ventricle ejection fraction, multivessel disease, multivessel PCI, and antiplatelet therapy. If the analysis highlighted a subgroup of patients at higher risk of adverse events, to understand if this finding is related to RMS implantation or to the characteristic itself, a propensity score matched analysis was conducted comparing patients of the SHERPA-MAGIC study with a matched cohort of patients receiving second generation drug eluting stent. The endpoint for the comparison between the two matched cohorts was POCE. Results: The mean age of the final study population was 56±9 years. 433 (78%) patients were men, and the most common clinical presentation was MI (n=402, 74%). At the median follow-up of 3.5 [2.6-4.3] years, the cumulative occurrence of the primary endpoint (vessel-oriented composite endpoints, VOCE, including cardiac death, target vessel MI, and ischemia-driven target vessel revascularization) was 37 (5.8%, 95%CI 4.1%-7.9%) and 54 (9.9%, 95% CI 7.5%-12.7%) patients met criteria for POCE. There was no significant difference among POCE in the subgroup analysis (Figure 1), with the exception of patients with MI as clinical presentation. As compared to patients admitted for chronic coronary syndrome, MI patients showed a significantly higher POCE rate (11.4 vs 5.6%, CI 8.5-14.9, p=0.04). Therefore, a propensity score matched analysis was conducted comparing MI patients of the SHERPA-MAGIC study with a matched cohort of MI patients from the Acute coRonary sYndrOmes proSpective regisTry Of Ferrara (ARYOSTO) study (NCT02438085) treated with second-generation DES. We did not find significant differences in the cumulative occurrence of POCE between SHERPA MAGIC and ARYOSTO (11.4% vs. 12.5% respectively, p=0.71) (Figure 2). Conclusions: The present analysis confirmed the safety and effectiveness of RMS across several subgroups of patients stratified by clinical and procedural characteristics. We found that MI patients had an higher occurrence of POCE, but this was not related to RMS implantation. Indeed, a similar MI population treated with second generation DES showed the same long-term outcome.Fig 1POCE difference between subgroupsFig 2Propensity matched MI populations
- 9 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (Supplement)
Open AccessPatient-level outcomes of patients undergoing resorbable magnesium scaffold (RMS) implantation stratified according to different subgroups: a post-hoc analysis of SHERPA MAGIC study
Background: The SHERPA-MAGIC is an investigator-driven, multicenter, prospective, single-arm study that enrolled patients undergoing resorbable magnesium scaffold (RMS) implantation in 18 Italian centers. The results from the first 543 patients supported the safety and long-term performance of RMS in a real-world population. Purpose: The present post-hoc analysis aimed to assess differences in adverse events at patient-level (patient-oriented composite endpoints, POCE, defined as the composite of all-cause death, myocardial infarction -MI- and ischemia-driven coronary revascularization) at the longest follow-up between different subgroups of the final study population (n=543). Methods: We identified the subgroups according to different variables: age, sex, cardiovascular risk factors, clinical presentation, left ventricle ejection fraction, multivessel disease, multivessel PCI, and antiplatelet therapy. If the analysis highlighted a subgroup of patients at higher risk of adverse events, to understand if this finding is related to RMS implantation or to the characteristic itself, a propensity score matched analysis was conducted comparing patients of the SHERPA-MAGIC study with a matched cohort of patients receiving second generation drug eluting stent. The endpoint for the comparison between the two matched cohorts was POCE. Results: The mean age of the final study population was 56±9 years. 433 (78%) patients were men, and the most common clinical presentation was MI (n=402, 74%). At the median follow-up of 3.5 [2.6-4.3] years, the cumulative occurrence of the primary endpoint (vessel-oriented composite endpoints, VOCE, including cardiac death, target vessel MI, and ischemia-driven target vessel revascularization) was 37 (5.8%, 95%CI 4.1%-7.9%) and 54 (9.9%, 95% CI 7.5%-12.7%) patients met criteria for POCE. There was no significant difference among POCE in the subgroup analysis (Figure 1), with the exception of patients with MI as clinical presentation. As compared to patients admitted for chronic coronary syndrome, MI patients showed a significantly higher POCE rate (11.4 vs 5.6%, CI 8.5-14.9, p=0.04). Therefore, a propensity score matched analysis was conducted comparing MI patients of the SHERPA-MAGIC study with a matched cohort of MI patients from the Acute coRonary sYndrOmes proSpective regisTry Of Ferrara (ARYOSTO) study (NCT02438085) treated with second-generation DES. We did not find significant differences in the cumulative occurrence of POCE between SHERPA MAGIC and ARYOSTO (11.4% vs. 12.5% respectively, p=0.71) (Figure 2). Conclusions: The present analysis confirmed the safety and effectiveness of RMS across several subgroups of patients stratified by clinical and procedural characteristics. We found that MI patients had an higher occurrence of POCE, but this was not related to RMS implantation. Indeed, a similar MI population treated with second generation DES showed the same long-term outcome.Fig 1POCE difference between subgroupsFig 2Propensity matched MI populations
- Open Access
- 8 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5844
Functional (Re)Development of SYNTAX Score II 2020: Predictive Performance and Risk Assessment
The present study investigates the prognostic value of the Syntax Score II 2020 corrected for flow-limiting lesions and its ability to better address treatment by benefit prediction among patients with left main or multivessel disease. We analyzed 1274 patients from the HALE-BOPP cohort and integrated the Syntax Score II 2020 with the result of the fractional flow reserve (FFR) evaluation. Absolute risk difference (ARD) between surgical and percutaneous revascularization was calculated for anatomic and functional Syntax Score II 2020 predicted mortality. The ARD allowed to stratify the population into two large categories: “coronary artery bypass graft (CABG) better” with ARD ≥ 4.5% and “CABG–percutaneous coronary intervention (PCI) equipoise” with ARD < 4.5%. The mean global anatomical Syntax Score was 15.5 ± 9.2, whereas the functional one was 9.5 ± 10 (p < 0.01). Using the anatomic Syntax Score II 2020, 881 patients had a CABG-PCI equipoise. This number increased to 1041 after considering only flow-limiting lesions by FFR (p < 0.001); therefore, 40% of CABG better patients were reclassified within the CABG-PCI equipoise category. Kaplan–Maier curves showed similar actual survival rates for patients originally with CABG-PCI equipoise and those reclassified, in both cases higher than those from CABG better patients (p < 0.01). The integration between Syntax Score II 2020 and physiology is feasible, and merging clinical, anatomic and functional data allows for better risk prediction and therapeutic guidance.
- 8 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5844
Open AccessFunctional (Re)Development of SYNTAX Score II 2020: Predictive Performance and Risk Assessment
The present study investigates the prognostic value of the Syntax Score II 2020 corrected for flow-limiting lesions and its ability to better address treatment by benefit prediction among patients with left main or multivessel disease. We analyzed 1274 patients from the HALE-BOPP cohort and integrated the Syntax Score II 2020 with the result of the fractional flow reserve (FFR) evaluation. Absolute risk difference (ARD) between surgical and percutaneous revascularization was calculated for anatomic and functional Syntax Score II 2020 predicted mortality. The ARD allowed to stratify the population into two large categories: “coronary artery bypass graft (CABG) better” with ARD ≥ 4.5% and “CABG–percutaneous coronary intervention (PCI) equipoise” with ARD < 4.5%. The mean global anatomical Syntax Score was 15.5 ± 9.2, whereas the functional one was 9.5 ± 10 (p < 0.01). Using the anatomic Syntax Score II 2020, 881 patients had a CABG-PCI equipoise. This number increased to 1041 after considering only flow-limiting lesions by FFR (p < 0.001); therefore, 40% of CABG better patients were reclassified within the CABG-PCI equipoise category. Kaplan–Maier curves showed similar actual survival rates for patients originally with CABG-PCI equipoise and those reclassified, in both cases higher than those from CABG better patients (p < 0.01). The integration between Syntax Score II 2020 and physiology is feasible, and merging clinical, anatomic and functional data allows for better risk prediction and therapeutic guidance.
- Open Access
- 1 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 23 (Supplement)
197 Angio-based index of microcirculatory resistance for the assessment of the coronary resistance: a proof of concept study
The study of coronary microcirculation has gained increasing consideration and importance in cath-lab. Despite the increase of evidence its use still remains very limited. QFR is a novel angio-based approach for the evaluation of coronary stenosis. The aim of our study was to use the QFR assessment in stable patients to recreate the IMR formula and to correlate the result of the two techniques. From 1 June 2019 to 29 February 2019, 200 patients with CCS and indication of coronary artery angiography and referred to the cath-lab of the University Hospital of Ferrara (Italy) were enrolled. After baseline coronary angiogram, quantitative flow ratio, fractional flow reserve and index of microcirculatory resistance evaluation were performed. Pearson correlation (r) between Angio-based index of microcirculatory resistance (A-IMR) and IMR 0.32 with R2 = 0.098, P = 0.03: McNemar test showed a difference between the two test of 6.82% with 95% CI from −12.05% to 22.89%, which is not significant (P = 0.60). Bland and Altman plot showed a mean difference of 23.3 (from −26.5 to 73.1). Sensitivity, specificity, NPV and PPV were 70%, 83.3%, 75% and 70% for A-IMR value > 44.2. The area under the ROC curve for A-IMR was 0.76 (95% CI: 0.61–0.88, P = 0.0003). We have validated for the first time the formula of the A-IMR, a tool for the calculation of microvascular resistance which does not require the use of pressure guides and the induction of hyperemia
- 1 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 23 (Supplement)
Open Access197 Angio-based index of microcirculatory resistance for the assessment of the coronary resistance: a proof of concept study
The study of coronary microcirculation has gained increasing consideration and importance in cath-lab. Despite the increase of evidence its use still remains very limited. QFR is a novel angio-based approach for the evaluation of coronary stenosis. The aim of our study was to use the QFR assessment in stable patients to recreate the IMR formula and to correlate the result of the two techniques. From 1 June 2019 to 29 February 2019, 200 patients with CCS and indication of coronary artery angiography and referred to the cath-lab of the University Hospital of Ferrara (Italy) were enrolled. After baseline coronary angiogram, quantitative flow ratio, fractional flow reserve and index of microcirculatory resistance evaluation were performed. Pearson correlation (r) between Angio-based index of microcirculatory resistance (A-IMR) and IMR 0.32 with R2 = 0.098, P = 0.03: McNemar test showed a difference between the two test of 6.82% with 95% CI from −12.05% to 22.89%, which is not significant (P = 0.60). Bland and Altman plot showed a mean difference of 23.3 (from −26.5 to 73.1). Sensitivity, specificity, NPV and PPV were 70%, 83.3%, 75% and 70% for A-IMR value > 44.2. The area under the ROC curve for A-IMR was 0.76 (95% CI: 0.61–0.88, P = 0.0003). We have validated for the first time the formula of the A-IMR, a tool for the calculation of microvascular resistance which does not require the use of pressure guides and the induction of hyperemia
- Open Access
- 18 February 2020
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 22 (3) , 561-563
Index of Microcirculatory Resistance Assessment in Patients with New Diagnosis of Left Ventricular Dilatation Without Significant Coronary Artery Lesions: IMPAIRED Pilot Trial
- 18 February 2020
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 22 (3) , 561-563
Open AccessIndex of Microcirculatory Resistance Assessment in Patients with New Diagnosis of Left Ventricular Dilatation Without Significant Coronary Artery Lesions: IMPAIRED Pilot Trial